Immune Repertoire Sequencing Market Size & Share, Growth Trends 2035

Global Market Size, Forecast, and Trend Highlights Over 2023 - 2035

Immune Repertoire Sequencing Market size is set to reach USD 3 Billion by the end of 2035, growing at a CAGR of 7% during the forecast period, i.e., 2023-2035. In the year 2022, the industry size of immune repertoire sequencing was around USD 1 Billion. The market is primarily driven by the escalating government encouragement for pharmacogenomics-based drug recovery. Furthermore, growth in multiple therapeutic areas such as cardiology, pain management, oncology, infectious diseases, and others is estimated to boost the market expansion in the projected period.

Additionally, the industry has been driven by many organizations seeking answers to biomarkers of the immune system. Mergers and acquisitions are also driving the market. More collaboration, acquisition, and agreement among the market players are majorly contributing to the industry growth. In order to produce effective and creative immunotherapies ArcherDX and Ambry Genetics joined hands in March 2018.

Get more information on this report: Request Free Sample PDF

Immune Repertoire Sequencing Market: Key Insights

Base Year	2022
Forecast Year	2023 – 2035
CAGR	~7%
Base Year Market Size	~USD 1 billion
Forecast Year Market Size	~USD 3 billion
Regional Scope	North America (U.S., and Canada) Latin America (Mexico, Argentina, Rest of Latin America) Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific) Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Immune Repertoire Sequencing Market: Growth Drivers and Challenges

Growth Drivers

Increasing Number of Launches of Novel Products – Escalating number of launches of novel products and a growing number of research and development activities carried out by key market players are estimated to propel the market demand in the predicted period. In order to characterize human B cells a company named ArcherDX launched Archer Immunoverse B cell Receptor assays in 2017. As per a Cold Spring Harbour Laboratory study, Stanford University researchers used immune repertoire sequencing to recognize the disease-associated symptom in the immune system of patients suffering from an autoimmune disease named systemic sclerosis-related pulmonary disease.
Rising Government Funding to Improve the Healthcare Infrastructure – Governments of various regions are offering investments and funding in order to improve the healthcare infrastructure all across the globe, which further boosts the growth of this market. As immune repertoire sequencing plays a vital role in a couple of therapeutic areas.
High Demand for Personalized Medicines - Rising demand for personalized medicine is expected to have a positive impact on the growth of the global immune repertoire sequencing market. Moreover, promoting the role of next-generation immune repertoire sequencing for personalized immune regulation is expected to surely support the market growth.

Challenges

Accuracy Differences and Partial Techniques Utilization - Distinguishing biological changes from errors and biases introduced at various stages is a challenge in immune repertoire sequencing. Conventional and new bioinformatics techniques such as high-throughput screening and Haystack heuristics fall short due to their poor scalability and sensitivity and their limitations in providing sufficient and reliable data. Moreover, inconsistencies in data acquisition and processing in different laboratories, and barriers in immune repertoire sequencing systems are some of the significant reasons that may limit the growth of the immune repertoire sequencing market.
Lack of Skilled Personnel in Lower Economic Regions
Discrepancies in Data Collection

Immune Repertoire Sequencing Segmentation

Product Type (Instruments, Assay Kits)

The assay kits segment in the immune repertoire sequencing market is set to witness the highest revenue share of 60% by the end of 2035. Assay kits are distributed into TCR kits and BCR kits. The TCR is a significant part of the human adaptive immune system. With the help of this system pathogenic are being identified, recalled, and destroyed. Therefore, various companies are signing agreements and merging in order to offer repertoire sequencing kits for a specific type of immunotherapy.

End User (Pharmaceutical Companies, Research Institutes, Diagnostic Labs)

The immune repertoire sequencing market from the pharmaceutical segment is poised to experience the largest demand throughout the projected period. Pharmaceutical companies primarily use immune repertoire sequencing to recognize and validate potential therapeutic targets. By knowing the functionality and diversity of immune cells and receptors they can make drugs that can modulate immune responses.

Moreover, pharmaceutical companies often collaborate with research organizations, academic institutions, and sequencing technology providers for advanced immune repertoire sequencing research.

Our in-depth analysis of the global market includes the following segments:

Product Type	Instruments Assay Kits
Application	Cancer Immunotherapy Biomarker Discovery Autoimmune Diseases Vaccine Development and Efficacy Transplant Rejection and Tolerance Infectious Diseases
End User	Pharmaceutical Companies Research Institutes Diagnostic Labs

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Immune Repertoire Sequencing Industry - Regional Synopsis

North American Market Forecast

The immune repertoire sequencing market in North America is projected to occupy the largest share over the period between 2023 – 2035. This can be ascribed to the high health spending, and strong presence of market players in the region, especially in the United States and Canada. According to the Centers for Medicare & Medicaid Services (CMS), health spending in the United States grew by 9.7% in 2020, reaching a value of USD 4.1 trillion, or USD 12,530 per person. The market is also anticipated to grow with escalating demand for immunotherapy for cancer and other infectious diseases.

APAC Market Statistics

The immune repertoire sequencing market in the Asia Pacific region is estimated to observe noteworthy market demand throughout the estimated period. This can be attributed on the back of the increasing number of international collaborations for immune repertoire sequencing in the region.

In addition, the focus of countries, namely China and Japan, on the integration of new technologies in the healthcare sector is also expected to drive market growth significantly in the coming years.

Get more information on this report: Request Free Sample PDF

Companies Dominating the Immune Repertoire Sequencing Market

Agilent Technologies, Inc
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Illumina, Inc.
Pacific Biosciences of California, Inc
QIAGEN N.V.
Thermo Fisher Scientific, Inc.
F. Hoffmann-La Roche AG
Takara Bio, Inc
Oxford Nanopore Technologies, Ltd
BGI Group
Atreca Inc

In The News

BGI and Gencove announced the extension of the agreement for offering low-pass whole genome sequencing and analysis service to improve global health and sustainability.
Thermo Fisher introduced a new suite of immune repertoire assays that will help identify potentially malignant clones of T-cells and B-cells.

Key Questions Answered in the Report

1) What are the major factors driving the growth of the immune repertoire sequencing market?

Ans: The major factors driving market growth are the increasing number of launches of novel products, and rising government funding to improve the healthcare infrastructure.

2) What would be the CAGR of the immune repertoire sequencing market over the forecast period?

Ans: The market is anticipated to attain a CAGR of 7% over the forecast period, i.e., 2023 â€“ 2035.

3) Who are the major players dominating the immune repertoire sequencing market?

Ans: The major players in the market are Agilent Technologies, Inc, Illumina, Inc., Pacific Biosciences of California, Inc, QIAGEN N.V., Thermo Fisher Scientific, Inc., and others.

4) Which segment captures the largest market size in end users in the immune repertoire sequencing market?

Ans: The pharmaceutical companies segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

5) Which region will provide more business opportunities for the growth of the immune repertoire sequencing market in the future?

Ans: The market in North America is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.